Summary
Forty postmenopausal women with a former Colles' fracture were enrolled in a 1-year study to determine the dose-effect relationship of nasal salmon calcitonin (SCT) on bone mass. They were randomized to receive either placebo, 50, 100, or 200 IU per day of SCT given as a nasal spray. The rate of change in the bone mineral content of the lumbar spine was 0.7, 0.2, 1.1, and 2.0 gHA per year, respectively, and the rate of change in the bone mineral content in the forearm was −0.4, −0.1, 0.0, and −0.1 AU per year, respectively. The rate of change in the bone mineral content of the lumbar spine in patients receiving 200 IU of SCT per day differed significantly from zero (P<0.01). Except for one patient, who experienced intolerable nausea, no systemic side effects were observed. Seven patients withdrew, two patients from nasal intolerance to the spray. These preliminary data suggest that SCT given by the nasal route has a positive and dose-dependent effect on spinal bone mass, but affects forearm bone mass only minimally.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303
Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8
Gennari C, Chierichetti SM, Bigazzi S, Fusi L, Gonelli S, Ferrara R, Zacchei F (1985) Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Therap Res 38:455–464
Pontiroli AE, Alberetto M, Pozza G (1985) Intranasal calcitonin and plasma calcium concentrations in normal subjects. Br Med J 290:1390–1391
Reginster JY, Albert A, Franchimont P (1985) Salmon calcitonin nasal spray in Paget's disease of bone: preliminary results in five patients. Calcif Tissue Int 37:577–580
Prockop DJ, Kivirikko KI (1967) Relationship of hydroxyproline excretion in urine to collagen metabolism. Ann Int Med 66:1243–1266
Nielsen KH, Thomsen K, Eriksen EF, Charles P, Storm T, Mosekilde L (1988) The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects Bone Miner 4:105–113
Christiansen C, Riis BJ, Pødenphant J, Johansen JS (1987) Intranasal calcitonin in the treatment of postmenopausal osteoporosis. In: Christiansen C, Johansen JS, Riis BJ (eds) Ostoporosis 1987. Nørhaven A/S, Viborg, Denmark, pp 853–856
Reginster JY, Albert A, Lecart MP, Lambelin P, Denis D, Deroisy R, Fontaine MA, Franchimont P (1987) One-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet ii:1481–1483
Reginster JY, Denis D, Albert A, Franchimont P (1987) Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. Bone Miner 2:133–140
Nüesch E, Schmidt R (1980) Comparative pharmacokinetics of calcitonins. In: Pecile A (ed) Calcitonin 1980: Chemistry, physiology, pharmacology and clinical aspects. Excerpta Medica, Amsterdam (ICS Nr 540), pp 352–364
Thamsborg G, Storm TL, Brinch E, Sykulski R, Fogh-Andersen N, Holmegaard SN, Sørensen OH (1990) The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium. Calcif Tissue Int 46:5–8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thamsborg, G., Storm, T.L., Sykulski, R. et al. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 48, 302–307 (1991). https://doi.org/10.1007/BF02556148
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02556148